AlphAIalphai — Financial news for AI agents
rttnews.comSEP 32 min read$SMMT

Summit Therapeutics Stock Rises 11%

Summit Therapeutics (SMMT) shares rose 11.23% to $16.24 on positive Phase III study results for ivonescimab in lung cancer. The company's partner, Akeso, reported significant overall survival improvements over pembrolizumab. The stock's 52-week range is $12.07 to $29.23.

Original reporting
rttnews.com
Published Sep 3, 2026, 6:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 6:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Summit Therapeutics Stock Rises 11% — source image
Source · rttnews.com
Decision brief

The 30-second read

$SMMTBullishHigh
01

Why it matters

The survival benefit over pembrolizumab suggests a differentiated therapeutic profile.

02

Market read

First report of pivotal trial results; immediate price impact and sector uplift.

03

What to watch

Potential competition from other PD-L1 inhibitors could limit market share.

Relevance 8/10Novelty 8/10Timing: intraday today

Background

Summit Therapeutics partnered with Akeso Inc. for ivonescimab, a PD-L1 targeting antibody.

Company-level read

Ticker impact

$SMMTBullishHigh confidence
Context

Phase III HARMONi-2 overall survival data released, driving an 11% intraday price rise.

Expected impact

Further upside expected if data holds up; potential 5-10% rally.

Evidence & confidence

First disclosure of pivotal trial data; market already reacting, indicating strong sentiment.

Market effects

Sector

Positive NSCLC data may lift other biotech firms developing immunotherapies.

Regional

US biotech sector gains modestly on the news.

Global

Limited to oncology and biotech investors worldwide.

Counterpoint

What could challenge this read

Data may not translate into commercial success without regulatory approval.

Key entities

  • company
    Summit Therapeutics Inc.

    Biotech firm developing ivonescimab.

  • partner
    Akeso Inc.

    Collaborator providing trial data analysis.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 3
$SMMTMed

Why is Summit Therapeutics stock surging today?

Summit Therapeutics (SMMT) stock rose 11.6% after its partner Akeso Inc. reported positive results from a Phase III study of ivonescimab. The trial met its overall survival endpoint, showing a survival advantage over pembrolizumab. Analysts remain divided, with some maintaining positive ratings. The FDA is set to review the lung cancer indication in November. The broader market also gained, supporting the rally.

investing.com5 min
SEP 3
$SMMTLowAI 8/10

Summit Therapeutics stock rises on positive survival data

Summit Therapeutics (SMMT) shares rose 4.8% premarket after partner Akeso reported positive overall survival data from a Phase III lung cancer trial. Ivonescimab showed a significant survival benefit over pembrolizumab in the HARMONi-2 study, though specific details were not disclosed. Akeso received marketing approval in China, but the drug remains investigational in Summit's territories. Analysts maintained a Neutral rating, citing insufficient data to change their view.

investing.com2 min
SEP 3
$SMMTMedAI 8/10

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in

Akeso Inc. reported positive overall survival results from the HARMONi-2 study, showing ivonescimab monotherapy outperformed pembrolizumab in PD-L1-positive advanced NSCLC. Summit Therapeutics (SMMT) noted the findings, with ivonescimab approved in China and under investigation in other regions. The study's hazard ratio was 0.51 (p<0.0001). Summit is conducting further trials, including HARMONi-7 for PD-L1 high-expressing NSCLC.

biospace.com2 min
AUG 27
$SMMTHighAI 8/10

Summit Therapeutics (SMMT) Is Up 8.5% After Ivonescimab’s Phase III Biliary Cancer Survival Win

Summit Therapeutics (SMMT) rose 8.5% after partner Akeso's Phase III trial showed ivonescimab plus chemotherapy improved survival rates in advanced biliary tract cancer. The drug's success adds to its lung cancer data and ongoing FDA review. Summit projects $897.3M revenue and $169.7M earnings by 2029, with analysts estimating potential $2.5B revenue by 2029.

simplywall.st2 min